Replies to post #228407 on Cytodyn Inc (CYDY)

[kgromax]

It reminds me of Cathy Woods CEO of ARKK

Nope.

Cathie Woods is considered crazy by many. But she didn’t lie.

Misiu did lie when her financial interest was on the line.

Huge difference. If you dont see it when it is in front of your eyes, you are a perfect victim for this type of scammer. They need people like you to succeed.

[justdafactss]

.23 to $10? A lot of good that did misiu---

I am invested in CYDY since January of 2016,
I was VERY wealthy on the paper June 2020 , and I am losing on the paper a lot now,
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171287442

[fung_derf]

I started posting here right after the big run. I did so because someone here dared me to while I was posting elsewhere. Nothing has changed in my belief on the company.
However, it has been pretty obvious for some time, as I could see 3 1/2 years ago.
She deserves no praise because she has touted the product and the product hasn't happened. Surely you now know the stock price went up because the CEO was lying to you, and the SEC caught him. Are you saying misiu deserves the credit for this?

fung_derf

Member Level
Re: I_luv_cydy post# 79801

Monday, June 01, 2020 1:50:05 PM

Post#
81663
of 228410
Just look at the charting on this stock and you will realize it's going nowhere. IF the company were for real, trading volume would be growing, not shrinking.

A lesson for you all as this is how penny stocks work. It's always about what they plan to do with a lot of "if's" included. Not here to argue your future, just point out the obvious.

About CytoDyn
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.